ToplineDanish pharma giant Novo Nordisk on Wednesday reported better-than-expected earnings for 2023, propelled by a tsunami of demand for its blockbuster weight loss and diabetes drugs as new treatments emerge and compete for a slice of the growing market.Sales of Wegovy, an injectable prescription weight loss medicine, has helped boost profits for Novo ... [+] Nordisk.UCG/Universal Images Group via Getty Images Key FactsNovo Nordisk reported $33.7 billion of sales for 2023, an increase of 36% at constant ...

Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar.The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates (CER) to 232.3 billion kroner ($33.71 billion).Full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Financial Performance - Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023[3]. - Operating profit rose by 37% in Danish kroner and by 44% at constant exchange rates to DKK 102.6 billion[3]. - The company achieved a net profit of DKK 83,683 million in 2023, marking a 51% increase compared to 2022[14]. - Gross profit for 2023 was DKK 196,496 million, reflecting a 32% increase year-over-year, with a gross margin of 84.6%[14]. - The diluted earnings per share rose to DKK 18.62, a 52% increase from the previous year[14]. - Net sales for 2023 reached DKK 232,261 million, a 31% increase from 2022, and a 36% increase at constant exchange rates (CER)[14]. - Operating profit (EBIT) increased by 44% at CER to DKK 102,574 million, reflecting strong sales growth[61]. - Net profit increased by 51% to DKK 83,683 million, with diluted earnings per share rising by 52% to DKK 18.62[62]. - Free cash flow for 2023 was DKK 68.3 billion, with DKK 61.7 billion returned to shareholders[12]. Sales Growth - Sales in North America Operations surged by 50% in Danish kroner, while International Operations saw an 11% increase[3]. - Diabetes and Obesity care sales grew by 38% in Danish kroner to DKK 215.1 billion, driven by a 48% increase in GLP-1 diabetes sales and a 147% increase in Obesity care sales[3]. - Sales growth for 2024 is expected to be between 18% to 26% at CER, with operating profit growth projected at 21% to 29% at CER[81][82]. - Sales of the injectable GLP-1 product Ozempic reached DKK 95,718 million, a 60% increase from 2022[17]. - Sales of GLP-1-based products for type 2 diabetes increased by 48% in Danish kroner and by 52% at CER to DKK 123,132 million, with a global market share of 6.0%[22]. - Sales of Obesity care products increased by 147% in Danish kroner and by 154% at CER to DKK 41,632 million, driven by North America Operations and International Operations[37]. - Wegovy sales surged by 407% in Danish kroner and by 420% at CER to DKK 31,343 million, reflecting strong demand and a commercial relaunch in the US[37]. - Sales in North America Operations increased by 67% at CER, driven by Obesity care sales growing by 151% at CER[66]. Dividends and Shareholder Returns - The Board of Directors proposed a final dividend of DKK 6.40 per share for 2023, totaling an expected DKK 9.40 per share for the year[4]. - The total dividend per share for 2023 was DKK 9.40, also reflecting a 52% increase year-over-year[14]. - Proposed final dividends of DKK 28,557 million are included in retained earnings, reflecting the company's commitment to returning value to shareholders[139]. Research and Development - Novo Nordisk completed a phase 3 trial with IcoSema and initiated a phase 1 trial with oral amycretin in Obesity care[4]. - Research and development costs increased by 37% at CER to DKK 32,443 million, reflecting increased clinical trial activity[60]. - The phase 3a trial COMBINE 3 for IcoSema has been successfully completed, with results expected from two additional trials in the first half of 2024[93]. Market Share and Competitive Position - The diabetes value market share increased by 1.9 percentage points to 33.8%[12]. - Novo Nordisk's global diabetes market share improved to 33.8% from 31.9% over the past year[20]. - The estimated GLP-1 share of total diabetes prescriptions increased to 15.5% in the US compared to 10.7% 12 months ago[25]. - In North America, GLP-1 sales increased by 48% in Danish kroner and by 52% at CER, with a market share of 53.1%[25]. Sustainability and Social Responsibility - CO2 emissions from operations and transportation decreased by 34% compared to 2019 and by 8% compared to 2022[107]. - The Changing Diabetes in Children program has reached over 52,000 children by the end of 2023, representing a 27% increase compared to 2022, with a goal to reach 100,000 children by 2030[109]. - Novo Nordisk aims to achieve a balanced gender representation across all managerial levels and a minimum of 45% women and men in senior leadership positions by the end of 2025[110]. Future Outlook - For 2024, sales growth is expected to be between 18-26% at constant exchange rates, with operating profit growth projected at 21-29%[4]. - Capital expenditure for 2024 is anticipated to be around DKK 45 billion, aimed at expanding manufacturing facilities in Denmark and France[84]. - The company continues to focus on innovation and therapeutic advancements as part of its strategic aspirations[155].

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Novo Nordisk (NVO) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Novo Nordisk currently has an average b ...

Investors are always looking for stocks that are poised to beat at earnings season and Novo Nordisk A/S (NVO) , may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Novo Nordisk is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty goo ...

With shares of Novo Nordisk (NYSE: NVO) skyrocketing by more than 200% over the last three years thanks to the outrageous success of its type 2 diabetes drug called Ozempic, investors are eager to determine what other companies in biopharma might be capable of following the same trajectory.But, as wise investors know, the next success stories are unlikely to be created with the exact same strategies as today's winners. That means looking for potential in a slightly different market than the one Novo Nordisk ...

In the latest trading session, Novo Nordisk (NVO) closed at $105.49, marking a -1.37% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.22%. On the other hand, the Dow registered a gain of 0.36%, and the technology-centric Nasdaq increased by 0.32%.Coming into today, shares of the drugmaker had gained 4.14% in the past month. In that same time, the Medical sector gained 2.3%, while the S&P 500 gained 1.61%.Investors will be eagerly watching for the performance of Nov ...

Peloton Interactive (PTON -3.80%) needs a growth catalyst badly. The company's bikes were hot buys during the early stages of the pandemic amid lockdowns when people couldn't go to gyms to exercise. But as things have returned to normal, demand has stalled. Revenue is going in the wrong direction, and the business is nowhere near profitable.Enter TikTok. The social media platform is partnering with Peloton in a move that the bike maker hopes will help give its sales a much-needed boost. And given how helpfu ...

The European pharmaceutical sector looks set for a good year on strong cash flows and attractive valuations, according to UBS analysts. They picked out four stocks that could particularly benefit but left out weight-loss drug pioneer and market darling Novo Nordisk, and struck a bearish note on AstraZeneca. ...